Evidence map›Paper›PMID 35804983›Full record

ArticleCancers2022

Multiple Basal Cell Carcinomas in Immunocompetent Patients.

Paola Savoia, Federica Veronese, Lara Camillo, Vanessa Tarantino, Ottavio Cremona, Elisa Zavattaro

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Paola SavoiaDepartment of Health Sciences, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy.ORCID 0000-0002-1636-8411
Federica VeroneseAzienda Ospedaliera Universitaria Maggiore della Carità, c.so Mazzini 18, 28100 Novara, Italy.ORCID 0000-0001-6438-5171
Lara CamilloDepartment of Health Sciences, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy.
Vanessa TarantinoAzienda Ospedaliera Universitaria Maggiore della Carità, c.so Mazzini 18, 28100 Novara, Italy.
Ottavio CremonaVita-Salute San Raffaele University, Via Olgettina 58, 20132 Milan, Italy.ORCID 0000-0001-9462-1040
Elisa ZavattaroAzienda Ospedaliera Universitaria Maggiore della Carità, c.so Mazzini 18, 28100 Novara, Italy.ORCID 0000-0003-4537-3014
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe onset of multiple BCCs is a relatively common condition, not only among patients undergoing chronic treatment with immunosuppressant drugs, but also in the general population, although specific risk factors for immunocompetent patients have not been identified. A putative role of somatic mutations in the hedgehog pathway should be considered.

methodsThis study is a retrospective observation of all patients diagnosed and surgically treated for BCCs during 5 years at our Dermatological Division. For these patients, we evaluated clinical and histopathological characteristics and data about possible risk factors for BCC.

resultsFive-hundred and six patients affected by multiple BCCs, accounting for the 24.2% of the entire sample, have been identified. In these patients, the total number of BCCs was 1516, ranging from 2 to 11. Subjects affected by multiple BCCs were more frequently males, with an older age at diagnosis; multiple BCCs developed mainly on the trunk and were often represented by a nodular histotype. The multivariate analysis highlighted that male gender, older age, nodular BCC, or face involvement at the first diagnosis are risk factors for the development of multiple BCCs.

conclusionsThe frequency of multiple BCCs even among the non-immunocompromised population underlines the need to subject patients to a close surveillance program, to allow early diagnosis and treatment of additional cancers.

Indexed as

basal cell carcinomahedgehog pathwaymutational statusnon-melanoma skin cancerrisk factorsUV-exposure

Identifiers

PMID35804983
PMCPMC9264959
OpenAlexW4283752831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.